Detection of mutations in the hepatitis B virus polymerase gene

Clinical Chemistry

Volumn 49, Issue 6, 2003, Pages 989-992

  Kessler, Harald H ^a   Stelzl, Evelyn ^a   Marth, Egon ^a   Stauber, Rudolf E ^b  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B POLYMERASE; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; AUTOMATION; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA SEQUENCE; ELECTROPHORESIS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; VIRUS DETECTION; VIRUS GENE; VIRUS MUTATION; VIRUS RESISTANCE;

AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENE PRODUCTS, POL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES;

ANIMALIA; DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0038697567     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.6.989     Document Type: Article

References (12)

1. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997;25:241-4.
2. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
3. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
4. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region [Review]. Hepatology 2001;33:751-7.
5. Niesters HGM, De Man RA, Pas SD, Fries E, Osterhaus ADME. Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002;51:695-9.
6. Allen MI, Gauthier J, Deslauriers M, Bourne EJ, Carrick KM, Baldanti F, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999;37:3338-47.
7. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J Clin Microbiol 2000;38:702-7.
8. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001;21:243-53.
9. Feld J, Locarnini S. Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. J Clin Virol 2002;25:267-83.
10. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9.
11. Fujie H, Moriya K, Shintani Y, Yotsuyanagi H, Iino S, Koike K. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology 2001;120:1564-5.
12. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002;17:165-70.